Sign In
Buy TEM
$50.56
-1.76 (-3.36%)
At Close: Jun 16, 2026
Tempus Announces Six Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer Annual Meeting 2025
08:30am, Wednesday, 05'th Nov 2025
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that six abstracts have been accepted for presen
3 Growth Stocks to Invest $1,000 in Right Now
05:25am, Wednesday, 05'th Nov 2025
Several companies offer turnkey access to AI data centers, but only Nebius Group is being called the Amazon Web Services of artificial intelligence. AI isn't replacing doctors and other caregivers, bu
Tempus (TEM) Reports Q3 Earnings: What Key Metrics Have to Say
07:31pm, Tuesday, 04'th Nov 2025
The headline numbers for Tempus (TEM) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estima
Tempus AI, Inc. (TEM) Q3 2025 Earnings Call Transcript
07:06pm, Tuesday, 04'th Nov 2025
Tempus AI, Inc. ( TEM ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Elizabeth Krutoholow - Vice President of Investor Relations & Competitive Intelligence Eric Lefkofsky -
Tempus AI (TEM) Reports Q3 Loss, Tops Revenue Estimates
06:46pm, Tuesday, 04'th Nov 2025
Tempus AI (TEM) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.25 per share a year ago.
Tempus Reports Third Quarter 2025 Results
04:01pm, Tuesday, 04'th Nov 2025
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarte
This AI Health Stock is Up Over 150% This Year—and It's Not Slowing Down
09:46am, Friday, 31'st Oct 2025
Tempus AI (NASDAQ:TEM) isn't an AI stock that immediately comes to mind when one thinks of machine-learning-driven technological innovators with disruptive potential.
TEM vs. EXAS: Which Genomics Player Offers Greater Upside?
10:02am, Wednesday, 29'th Oct 2025
Tempus AI's soaring genomics revenues and Exact Sciences' diagnostic breakthroughs spotlight two distinct routes to precision oncology growth.
Tempus to Participate in the Stifel 2025 Healthcare Conference
08:30am, Tuesday, 28'th Oct 2025
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that it will participate in the Stifel 2025 Healthcare Conference o
Tempus AI Enhances AI-Driven Diagnostics With Multiple FDA Approvals
10:21am, Monday, 27'th Oct 2025
TEM secures multiple FDA clearances in 2025, boosting its AI-driven diagnostic portfolio across oncology and cardiology.
Tempus to Report Third Quarter 2025 Financial Results on November 4
08:30am, Tuesday, 21'st Oct 2025
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter of 2025 on
Why Tempus AI Stock Raced More Than 5% Higher Today
06:36pm, Monday, 20'th Oct 2025
There was nothing artificial about the share price boost enjoyed by artificial intelligence (AI) specialist Tempus AI (TEM 5.29%). The company, which concentrates on applying AI functionalities to dru
Tempus AI Stock Before Q3 Earnings Release: To Buy or Not to Buy?
10:06am, Monday, 20'th Oct 2025
TEM's 48% surge, key FDA clearances and bold AI acquisitions set the stage for its Q3 earnings reveal.
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, a leader in genetic testing, and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), announced the publication of a peer-reviewed study in
Tempus AI Fuels Growth Through Strategic Biotech Collaborations
10:45am, Friday, 17'th Oct 2025
TEM expands its AI-driven growth with new collaborations in oncology, neurogenomics, and diagnostic innovation.
